Effect of medications on physical function and cognition in nursing home residents with dementia

Journal of the American Geriatrics Society

Volumn 62, Issue 6, 2014, Pages 1046-1055

  Dutcher, Sarah K ^a   Rattinger, Gail B ^b   Langenberg, Patricia ^c   Chhabra, Pankdeep T ^a   Liu, Xinggang ^d   Rosenberg, Paul B ^e,f   Leoutsakos, Jeannie Marie ^e,f   Simoni Wastila, Linda ^a   Walker, Loreen D ^a   Franey, Christine S ^a   Zuckerman, Ilene H ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d PHILIPS HEALTHCARE   (United States)

^e JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Health Division IMPAQ International   (United States)

Author keywords

activities of daily living; Alzheimer's disease; cognition; dementia; nursing home; psychotropic medication

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OXCARBAZEPINE; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE AND RELATED DEMENTIA; ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE PERFORMANCE SCALE; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICARE; NURSING HOME PATIENT; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ALZHEIMER'S DISEASE; COGNITION; DEMENTIA; NURSING HOME; PSYCHOTROPIC MEDICATION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 84902344711     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12838     Document Type: Article

References (50)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 2012: 131-168.
2. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
3. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-469.
4. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620.
5. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
6. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268.
7. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999; 318: 633-638.
8. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-241.
9. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-324.
10. Rattinger GB, Burcu M, Dutcher SK, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc 2013; 61: 723-733.
11. Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries. J Am Geriatr Soc 2007; 55: 1508-1516.
12. Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry 2012; 27: 1248-1257.
13. Sink KM, Holden KF, Yaffe K,. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005; 293: 596-608.
14. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-Analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-1960.
15. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009; 169: 867-873.
16. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163: 949-957.
17. Schneider LS, Dagerman KS, Insel P,. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-Analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
18. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: A retrospective cohort study. J Clin Psychiatry 2009; 70: 1340-1347.
19. Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831-839.
20. Parsons C, Briesacher BA, Givens JL, et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc 2011; 59: 1253-1259.
21. Barnes LL, Wilson RS, Bienias JL, et al. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 2005; 62: 685-691.
22. Lovheim H, Sandman PO, Karlsson S, et al. Sex differences in the prevalence of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2009; 21: 469-475.
23. Zuidema SU, de Jonghe JF, Verhey FR, et al. Predictors of neuropsychiatric symptoms in nursing home patients: Influence of gender and dementia severity. Int J Geriatr Psychiatry 2009; 24: 1079-1086.
24. Haywood WM, Mukaetova-Ladinska EB,. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Am J Geriatr Pharmacother 2006; 4: 273-286.
25. Rigaud AS, Traykov L, Latour F, et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12: 415-420.
26. Munro CA, Brandt J, Sheppard JM, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the Depression in Alzheimer's Disease Study (DIADS). Am J Geriatr Psychiatry 2004; 12: 491-498.
27. Buccaneer Computer Systems & Service Inc. Chronic Condition Data Warehouse Medicare Administrative Data User Guide, Version 2.0, 2013.
28. Taylor DH Jr, Fillenbaum GG, Ezell ME,. The accuracy of Medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol 2002; 55: 929-937.
29. Morris JN, Fries BE, Morris SA,. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci 1999; 54A: M546-M553.
30. Carpenter GI, Hastie CL, Morris JN, et al. Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment. BMC Geriatr 2006; 6: 7.
31. Morris JN, Fries BE, Mehr DR, et al. MDS cognitive performance scale. J Gerontol 1994; 49: M174-M182.
32. Hartmaier SL, Sloane PD, Guess HA, et al. The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set. J Am Geriatr Soc 1994; 42: 1173-1179.
33. Cohen-Mansfield J, Taylor L, McConnell D, et al. Estimating the cognitive ability of nursing home residents from the Minimum Data Set. Outcomes Manag Nurs Pract 1999; 3: 43-46.
34. Gruber-Baldini AL, Zimmerman SI, Mortimore E, et al. The validity of the Minimum Data Set in measuring the cognitive impairment of persons admitted to nursing homes. J Am Geriatr Soc 2000; 48: 1601-1606.
35. Smart KA, Herrmann N, Lanctot KL,. Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research. J Geriatr Psychiatry Neurol 2011; 24: 67-72.
36. Boustani MA, Campbell NL, Munger S, et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008; 4: 311-320.
37. Perlman CM, Hirdes JP,. The Aggressive Behavior Scale: A new scale to measure aggression based on the Minimum Data Set. J Am Geriatr Soc 2008; 56: 2298-2303.
38. Burrows AB, Morris JN, Simon SE, et al. Development of a Minimum Data Set-based depression rating scale for use in nursing homes. Age Ageing 2000; 29: 165-172.
39. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
40. Hernan MA, Brumback B, Robins JM,. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.
41. Faries DE, Kadziola ZA,. Analysis of longitudinal observational data using marginal structural models. In:, Faries DE, Leon AC, Haro JM, et al., eds. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Institute Inc., 2010, pp 211-230.
42. Mielke MM, Leoutsakos JM, Corcoran CD, et al. Effects of Food and Drug Administration-Approved medications for Alzheimer's disease on clinical progression. Alzheimers Dement 2012; 8: 180-187.
43. Munro CA, Longmire CF, Drye LT, et al. Cognitive outcomes after sertraline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 2012; 20: 1036-1044.
44. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry 2003; 60: 737-746.
45. Watson LC, Lehmann S, Mayer L, et al. Depression in assisted living is common and related to physical burden. Am J Geriatr Psychiatry 2006; 14: 876-883.
46. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-1538.
47. Rocca P, Marino F, Montemagni C, et al. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci 2007; 61: 622-629.
48. Simoni-Wastila L, Ryder PT, Qian J, et al. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17: 417-427.
49. Taylor DH Jr, Ostbye T, Langa KM, et al. The accuracy of Medicare claims as an epidemiological tool: The case of dementia revisited. J Alzheimers Dis 2009; 17: 807-815.
50. Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44: 471-477.